ArriVent Biopharma is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for difficult-to-treat diseases, particularly in oncology. Their lead candidate, firmonertinib, is being studied for its efficacy in treating non-small cell lung cancer (NSCLC) with specific genetic mutations, such as EGFR mutations and HER2 exon 20 insertions. The company employs a strategic approach to drug development, leveraging their team's extensive experience to design regulatory strategies that facilitate the approval process. They are committed to advancing a pipeline of novel oncology therapeutics, including next-generation antibody drug conjugates, through collaborations and partnerships that enhance their ability to bring these medicines to global patient populations.

ArriVent's research and development efforts are characterized by a focus on identifying and advancing differentiated medicines that address unmet medical needs. Their clinical trials, such as the FURTHER and FURVENT studies, aim to evaluate the safety and efficacy of firmonertinib in various patient populations with advanced or metastatic NSCLC. By establishing partnerships for in-licensing promising drug candidates and utilizing their business development expertise, ArriVent is building a competitive pipeline that aims to deliver innovative treatments to patients worldwide. Their commitment to collaboration and strategic development underscores their goal of maximizing the potential of their therapeutic candidates in the oncology space.

United States

ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.

ArriVent Biopharma

Company Details